繁
简
Market+ (iPhone)
Market+ (Android)
Mobile Site
US STOCKS
FUNDS
FX & CRYPTO
SH/SZ-HK
HK STOCKS
 
 
 
 
 
 
Quote Service
Market
Market
Quotes
Quotes
Analysis
Analysis
Commentary
Commentary
Warrants&CBBCs
Warrants&CBBCs
Warrants&CBBCs Overview
Warrants
CBBCs
ETF
ETF
MPF
MPF
Education
Members
Members
About Us
About Us

IPO Plus - IPO

To-be Listed
Name▼
/
Code▼
 Industry Offer Price Lot Size Entry Fee Closing Date
Grey Market Date▼
Listing Date▲
Xunfei Healthcare
02506.HK		 Application Software 82.8 50 N/A 2024/12/23 Data is not available 2024/12/30
InnoScience
02577.HK		 Semiconductors & Semiconductor Equipment 30.86-33.66 100 3,400 2024/12/23 Data is not available 2024/12/30
HealthyWay
02587.HK		 Health Care Services 7.8-8.8 500 4,444 2024/12/23 Data is not available 2024/12/30
ABBISKO-B (02256.HK)
Summary
We are a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. Since our inception in 2016, we have strategically designed and developed a pipeline of 14 candidates focused on oncology, including five candidates at clinical stage. Our product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. We have two Core ProductCandidates, ABSK011 and ABSK091, and 12 other pipeline product candidates. ABSK011 developed in-house is a potent and highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4); and ABSK091, licensed from AZ, and previously known as AZD4547, is a molecularly targeted product candidate and a highly potent and selective inhibitor of FGFR subtypes 1, 2 and 3. Our Core Product Candidates are primarily being developed for HCC, UC and GC at current stage.

We face fierce competition from existing products and product candidates under development in the entire oncology market, not only in the FGFR inhibitor market. In addition to approved oncology therapy options there are a large number of competing drug candidates currently under different clinical stages. According to Frost & Sullivan, the field of cancer treatment has developed significantly in the past decade. Treatment methods such as surgery, radiotherapy and chemotherapy have been widely utilized to treat cancer. Alternative treatments such as precision oncology and immuno-oncology are generally used only if the other therapy options are not suitable or effective on patients. Among the alternative treatments available, small molecule precision oncology therapies act on specific targets on cancer cells that are associated with cancer growth. Small molecule precision oncology therapies include selective inhibitors such as FGFR inhibitors, and non-selective kinase inhibitors and other types of inhibitors. Cactivities, and therefore may compete with the selective FGFR inhibitors. There are currently four non-selective kinase inhibitors approved for HCC, namely regorafenib, sorafenib, lenvatinib, cabozantinib, and no non-selective kinase inhibitors approved for UC or GC.

Selective kinase inhibitors targeting FGFR may target different FGFR subtypes, such as pan-FGFR or specific FGFR subtypes (e.g. FGFR4). In addition, there are currently three pan-FGFR inhibitors approved, namely pemigatinib, erdafitinib and infigratinib, and no FGFR inhibitors targeting specific FGFR subtypes approved. In addition, there are a total of 16 pan-FGFR inhibitor drug candidates (other than ABSK091) and nine FGFR4 drug candidates (other than ABSK011) under various stages of clinical development. For small molecule immuno-oncology drugs, for CSF-1R pathway, pexidartinib was the only CSF-1R inhibitor approved by the FDA and surufatinib (an angio-immuno kinase inhibitor targeting VEGFR, FGFR1 and CSF-1R) was the only NMPA approved drug that could target CSF-1R; in addition, a total of six drug candidates (other than ABSK021) were under various stages of clinical development globally; for CXCR4, plerixafor was the only marketed drug globally but was not approved for oncology indications, and three drug candidates, including our ABSK081 (mavorixafor), are under various stages of clinical development.

Our Core Product Candidates are FGFR4 and pan-FGFR inhibitors, respectively, which are considered to be small molecule precision oncology drug candidates. Our other product candidates are primarily small molecule precision oncology and small molecule immunooncology drug candidates. As a result, our drug candidates may not be used unless the conventional therapy options are not suitable or effective on patients. In addition, our small molecule precision oncology and small molecule immuno-oncology drug candidates face competition from the approved drugs and may not be selected unless the other approved drugs are not suitable or effective on patients. Furthermore, we compete with the various drug candidates under development and we may not successfully develop and/or market our products before the other drug candidates, or at all. Our Core Product Candidates are still at an early stage of development. We have completed a Phase Ia clinical trial for ABSK011 and a Phase I clinical trial for ABSK091, which have only generated limited safety and efficacy data that may not be used for a meaningful comparison against the data of the other drugs. In addition, FGFR inhibitors have been under development since at least 2014, according to the earliest post date of other clinical stage FGFR inhibitors, and only three pan-FGFR inhibitors have been approved, which implies that the development of FGFR inhibitors face significant challenges and uncertainties.

Our Company was founded with a focus on drug discovery, which we believe is the foundation of the entire drug development process. Our discovery capability is driven by an experienced team with solid drug discovery track record and our approach to identify high-quality molecules. Our three co-founders, Dr. XU Yao-Chang, Dr. YU Hongping and Dr.

CHEN Zhui, collectively have made contributions to dozens of discovery programs, a number of which led to successful commercialization, such as Ameile (almonertinib), Cymbalta (duloxetine), Balversa (erdafitinib), Reyvow (lasmiditan), Fu Laimei (PEG-loxenatide), Kisqali (ribociclib), Xinfu (flumatinib) and Venclexta (venetoclax). Leveraging the experience of our R&D team, we have built an innovation-driven discovery platform with comprehensive capabilities in cancer genomics and screening, computational and medicinal chemistry, and translational and biomarker science, which enables us to discover high-quality assets with efficiency. As of the Latest Practicable Date, our R&D team had advanced the first eight discovery programs into the IND-enabling stage at about two pre-clinical candidates per year since 2017, and continues to advance all of the other drug assets and programs into the next stage. We believe our pre-clinical candidates will lay the foundation for our future success and global growth.

Source: Abbisko-B (02256) Prospectus (IPO Date : 2021/09/30)
Listing Market MAIN
Industry Biotechnology
Background Others
Major Business Area N/A
Corporate Information
Substantial Shareholders XU Yao-Chang & Associates (17.00%)
Shi Yi (8.98%)
Qiming Corporate GP VI, Ltd. (7.15%)
Futu Trustee Limited (6.21%)
Directors XU Yao-Chang (Chairman and Chief Executive Officer and Executive Director)
CHEN Zhui (Senior Vice President and Executive Director)
YU Hongping (Senior Vice President and Executive Director)
SUN Hongbin (Independent Non-Executive Director)
SUN Piaoyang (Independent Non-Executive Director)
WANG Lei (Independent Non-Executive Director)
Company Secretary CHAN Yin Wah
Yu Hongping
Principal Bankers Ping An Bank
Solicitors Davis Polk & Wardwell
Auditors Ernst & Young
Registered Office 40th Floor, Dah Sing Financial Centre, No.248 Queen’s Road East, Wanchai, Hong Kong
Share Registrars Computershare Hong Kong Investor Services Ltd. [Tel: (852) 2862-8628]
Share Registrars Tel No (852) 2862-8628
Internet Address http://www.abbisko.com
Email Address IR@abbisko.com
Tel No (86 21) 6891-2098
Fax No
 
SITEMAP
AASTOCKS.com
 
 
Members
 
About Us
Market
Quotes
 
Analysis
News & Research
 
Commentary
 
Warrants&CBBCs
 
Warrants
 
CBBCs
 
US Stocks
Forex
 
Fund
 
MPF
Email: support@aastocks.com
AASTOCKS.COM LIMITED (阿斯達克網絡信息有限公司) All rights reserved.
Disclaimer
You expressly agree that the use of this app/website is at your sole risk.

AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd, Nasdaq, Inc., their respective holding companies and/or any subsidiaries of such holding companies, their Sources and/or other third party data provider(s) endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co.Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) make any express or implied offers, representations or warranties (including, without limitation, any warranty or merchantability or fitness for a particular purpose or use) regarding the Information.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) will be liable to any Subscriber or any other party for any interruption, inaccuracy, error, or omission, regardless of cause, in the Information or for any damages (whether direct or indirect, consequential, punitive, or exemplary) resulting from its use by any party.

AASTOCKS.com Limited shall not be liable for any failure or delay in performance of its obligations under this Disclaimer because of circumstances beyond its reasonable control, including but without limitation, acts of God, typhoons, rainstorms, other natural disasters, government restrictions, strikes, wars, virus outbreak, network failures or telecommunications failures.

Morningstar Disclaimer: Copyright © 2020 Morningstar, Inc. All Rights Reserved. The information, data, analyses and opinions ("Information") contained herein: (1) include the proprietary information of Morningstar and Morningstar’s third party licensors; (2) may not be copied or redistributed except as specifically authorised; (3) do not constitute investment advice; (4) are provided solely for informational purposes; and (5) are not warranted to be complete, accurate or timely. Morningstar is not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

The information and contents contained in this app/website are based on the analyses and interpretations of publicly available information obtained from sources believed to be reliable. Such analyses and information have not been independently verified and AASTOCKS.com Limited makes no guarantees to their accuracy, completeness, timeliness or correctness.

The information, financial market data, quotes, charts, statistics, exchange rate, news, research, analysis, buy and sell ratings, Education Center and other information on this app/website should be used as references only at your own discretion. Prior to the execution of a security or any other trade based upon the Information, you are advised to consult independent professional advice to verify pricing information or to obtain more detailed market information. AASTOCKS.com Limited is not soliciting any subscriber or app/website visitor to execute any trade. Any trades executed following the said information, commentaries and/or buy/sell ratings on this app/website are taken at your own risk for your own account.

AASTOCKS.com Limited provides the information and services on an "AS IS" basis. The information and contents on this app/website are subject to change without notice. AASTOCKS.com Limited reserves the right, in its sole discretion but without any obligation, to make improvements to, or correct any error or omissions in any portion of this app/website at any time.

The subscriber or app/website visitor agrees not to reproduce, retransmit, disseminate, distribute, broadcast, publish, circulate, sell or commercially exploit the information and contents on this app/website in any manner without the express written consent of AASTOCKS.com Limited.

Investment involves risk. You may make use of the Education Center of this website for academic reference purposes at your own discretion. AASTOCKS.com Limited cannot and does not give any assurance that the present or future buy/sell commentaries and signals on this app/website will be profitable. AASTOCKS.com Limited cannot guarantee, and the subscriber or app/website visitor should not assume, that the future performance will equal past performance.

AASTOCKS.com Limited may point to other sites that may be of interest to the subscriber or app/website visitor but for which AASTOCKS.com Limited has no responsibility and only provides this as a service to the subscriber or app/website visitor.

AASTOCKS.com Limited does not represent or endorse the accuracy or reliability of any information, advertisements or contents contained on, distributed through, or linked, downloaded or accessed from any of the services on this app/website. AASTOCKS.com Limited cannot and does not guarantee the quality or reliability of any products or information purchased or obtained by you as a result of an advertisement or any other information displayed on this app/website.

AATV is a video platform owned by AASTOCKS.com Limited.

You acknowledge that: (i) AATV is provided for information purposes only and, in particular, is not intended for trading purposes; (ii) AATV does not and none of the information contained in its program constitutes a solicitation, offer, opinion, or recommendation by us to buy or sell any security, or to provide legal, tax, accounting, or investment advice or services whether or not regarding the profitability or suitability of any security or investment; and (iii) AATV is not intended for use by, or distribution to, any person or entity in any jurisdiction or country where such use or distribution would be contrary to law or regulation.

The financial analysis or opinion expressed in the AATV programs is for reference and discussion only, and does not represent AASTOCKS.com Limited. Investors must make their own investment decisions based on their own investment objectives and financial situation. AASTOCKS.com Limited shall not, directly or indirectly, be liable, in any way, to you or any other person for any: (i) inaccuracies or errors in or omissions from AATV including, but not limited to, quotes and financial data; (ii) delays, errors, or interruptions in the transmission or delivery of AATV; or (iii) loss or damage arising therefrom or occasioned thereby, or by any reason of nonperformance.

AASTOCKS.com Limited reserves the right to change this Disclaimer at any time by posting changes online at this app/website. You are responsible for reviewing regularly information posted therein to obtain timely notice of such changes. Your continued use of this app / website after changes are posted constitutes your acceptance of this Agreement as modified by the posted changes.

The disclaimer herein shall be governed by the law of the Hong Kong Special Administrative Region of the People's Republic of China ("Hong Kong") and you agree to submit to the exclusive jurisdiction of the Hong Kong courts.

In the event of any discrepancy between the Chinese and English versions, the English version shall prevail.

Last updated on 6 January 2023.